Aprea Therapeutics, Inc. Expected to Earn Q2 2023 Earnings of ($1.47) Per Share (NASDAQ:APRE)

Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Rating) – Research analysts at HC Wainwright decreased their Q2 2023 EPS estimates for shares of Aprea Therapeutics in a research note issued on Tuesday, May 16th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($1.47) for the quarter, down from their prior estimate of ($1.06). The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($5.22) per share. HC Wainwright also issued estimates for Aprea Therapeutics’ Q3 2023 earnings at ($1.58) EPS, Q4 2023 earnings at ($1.95) EPS, FY2023 earnings at ($6.07) EPS, FY2024 earnings at ($1.78) EPS, FY2025 earnings at ($1.94) EPS, FY2026 earnings at ($1.39) EPS and FY2027 earnings at ($1.59) EPS.

Get Aprea Therapeutics alerts:

Separately, Maxim Group started coverage on Aprea Therapeutics in a report on Friday, March 10th. They set a “buy” rating for the company.

Aprea Therapeutics Stock Down 2.7 %

APRE opened at $3.74 on Thursday. The company’s 50-day moving average price is $4.27 and its 200 day moving average price is $7.09. Aprea Therapeutics has a fifty-two week low of $3.65 and a fifty-two week high of $25.80. The firm has a market cap of $13.94 million, a price-to-earnings ratio of -0.04 and a beta of 0.96.

Hedge Funds Weigh In On Aprea Therapeutics

Several institutional investors have recently modified their holdings of APRE. AIGH Capital Management LLC bought a new stake in Aprea Therapeutics in the 1st quarter valued at about $1,533,000. Renaissance Technologies LLC grew its position in Aprea Therapeutics by 4.7% in the 2nd quarter. Renaissance Technologies LLC now owns 311,754 shares of the company’s stock worth $234,000 after purchasing an additional 13,854 shares during the last quarter. Sio Capital Management LLC acquired a new stake in shares of Aprea Therapeutics in the first quarter valued at approximately $1,243,000. Millennium Management LLC raised its holdings in shares of Aprea Therapeutics by 35.7% during the fourth quarter. Millennium Management LLC now owns 164,626 shares of the company’s stock valued at $53,000 after buying an additional 43,293 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Aprea Therapeutics during the second quarter worth approximately $54,000. Institutional investors own 7.66% of the company’s stock.

About Aprea Therapeutics

(Get Rating)

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors.

Featured Stories

• Get a free copy of the StockNews.com research report on Aprea Therapeutics (APRE)
• It’s Time To Take Another Bite Of Take-Two Interactive 
• Zoetis Declares New Dividend, Hinting At Undervaluation
• Good News For Walmart Isn’t So Great For Everybody Else
• Eagle Materials, Answering America’s Building Supply Needs
• Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market

Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.